Novo Nordisk CagriSema -15%: Study Shock Causes Stock Plunge

Is Novo Nordisk at risk of losing its grip on the booming obesity market after the disappointing CagriSema data in its duel with Eli Lilly?

What is weighing heavily on Novo Nordisk today?

The immediate trigger for the stock plunge is the topline results from the Phase 3 study REDEFINE-4, released today, involving Novo Nordisk CagriSema. In this open-label head-to-head study, the combination drug was directly compared with Tirzepatide, the active ingredient behind Eli Lilly’s blockbuster drugs Zepbound and Mounjaro. After 84 weeks, patients on CagriSema achieved an average weight loss of 23.0%, while Tirzepatide performed significantly better at 25.5%, assuming all participants adhered to the treatment.

The study was supposed to demonstrate that CagriSema would achieve at least comparable weight loss to its U.S. competitor. However, this goal—the primary endpoint of the non-inferiority analysis—was clearly missed. This confirms what investors have feared since the initial data in December 2024: Novo Nordisk CagriSema is not the anticipated “Lilly-killer” in terms of pure efficacy comparison.

As of now, Novo Nordisk’s U.S. stock is trading at $47.42, down from $48.45 on Friday, a decrease of 2.13%. However, in pre-market trading, the stock has plummeted to $40.17, a drop of around 15%. This marks a new four-year low, reducing the company’s market value by billions in just a few minutes of trading.

How bad are the CagriSema data for Novo Nordisk?

The raw numbers are shocking for investors, especially since the obesity market is considered one of the largest growth drivers in the pharmaceutical industry. According to company statements and the data presented today, Novo Nordisk CagriSema achieved a notable weight reduction of 23%, but the 2.5 percentage point gap compared to Tirzepatide weighs heavily against it. Reuters reports that the primary endpoint of non-inferiority is officially deemed missed, while CNBC refers to a failure in achieving the desired equivalence in weight loss.

Nevertheless, management is attempting to smooth over the situation. Back in December, Novo Nordisk submitted a registration application for CagriSema to the U.S. FDA based on the pivotal REDEFINE-1 and -2 studies. A decision is not expected until late 2026. The company points out that CagriSema has delivered strong data in other studies and has shown additional benefits beyond just weight loss. Details on this will be presented at various conferences throughout the year.

Strategically, it remains important: Novo Nordisk is already well-positioned in the market with its established GLP-1 products Wegovy and Ozempic. Recently, the company reported very strong demand for the new Wegovy pill, which should significantly ease access to therapy. While Novo Nordisk has an attractive product mix, the anticipated technological leap from Novo Nordisk CagriSema over Eli Lilly is currently absent—and that is what the market is recalibrating today.

Novo Nordisk CagriSema (NVO) Stock Chart — 1-Year Chart · Source: stocknewsroom.com

How are investors and analysts reacting to Novo Nordisk CagriSema?

The mood on the markets is correspondingly frosty. In Copenhagen, the stock dropped by more than 10% in the morning, and deep red terrain dominates in Europe. Observers are calling it a “body blow” that shakes confidence in Novo Nordisk’s long-term dominance in the obesity boom. While the stock of rival Eli Lilly benefits from the news, the CagriSema shock pushes Novo Nordisk back into a defensive position.

Concrete new price targets from investment banks like Citigroup, Goldman Sachs, or RBC Capital Markets have not yet emerged by Monday morning, but previous ratings were already under scrutiny. Many analysts had factored in significant additional revenues from Novo Nordisk CagriSema in their growth models. Following the clear loss in the head-to-head comparison with Tirzepatide, it is likely that valuation models will be adjusted and medium-term revenue estimates will be cut.

On the other hand, more optimistic investors point to structural trends: The global obesity market is growing rapidly, and the strong demand for the Wegovy pill confirms that Novo Nordisk remains a central player—even if CagriSema takes on a more supplementary role and does not conquer the market’s peak. For long-term investors, it will now be crucial whether management credibly outlines a strategy for how to technologically and commercially catch up with Eli Lilly.

Bottom Line

The REDEFINE-4 data released today represent a significant setback for Novo Nordisk CagriSema, sending the stock to a new four-year low. While Wegovy, Ozempic, and the new oral Wegovy formulation remain strong growth drivers, Eli Lilly’s lead in innovative obesity therapies is noticeably widening. The coming months with detailed study data and potential adjustments to analyst models will show whether CagriSema can still become a growth joker for Novo Nordisk or remains a missed opportunity.